356 related articles for article (PubMed ID: 28421296)
1. Metabolite signatures of doxorubicin induced toxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Chaudhari U; Ellis JK; Wagh V; Nemade H; Hescheler J; Keun HC; Sachinidis A
Amino Acids; 2017 Dec; 49(12):1955-1963. PubMed ID: 28421296
[TBL] [Abstract][Full Text] [Related]
2. MicroRNAs as early toxicity signatures of doxorubicin in human-induced pluripotent stem cell-derived cardiomyocytes.
Chaudhari U; Nemade H; Gaspar JA; Hescheler J; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Dec; 90(12):3087-3098. PubMed ID: 26842497
[TBL] [Abstract][Full Text] [Related]
3. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
4. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells.
Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y
Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase IIα to IIβ in human stem cell derived cardiomyocytes.
Cui N; Wu F; Lu WJ; Bai R; Ke B; Liu T; Li L; Lan F; Cui M
J Cell Mol Med; 2019 Jul; 23(7):4627-4639. PubMed ID: 31106979
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
Cunha-Oliveira T; Ferreira LL; Coelho AR; Deus CM; Oliveira PJ
Toxicol Appl Pharmacol; 2018 Jun; 348():1-13. PubMed ID: 29653124
[TBL] [Abstract][Full Text] [Related]
7. Assessment of acute and chronic toxicity of doxorubicin in human induced pluripotent stem cell-derived cardiomyocytes.
Louisse J; Wüst RCI; Pistollato F; Palosaari T; Barilari M; Macko P; Bremer S; Prieto P
Toxicol In Vitro; 2017 Aug; 42():182-190. PubMed ID: 28456566
[TBL] [Abstract][Full Text] [Related]
8. Functional cardiotoxicity assessment of cosmetic compounds using human-induced pluripotent stem cell-derived cardiomyocytes.
Chaudhari U; Nemade H; Sureshkumar P; Vinken M; Ates G; Rogiers V; Hescheler J; Hengstler JG; Sachinidis A
Arch Toxicol; 2018 Jan; 92(1):371-381. PubMed ID: 28940058
[TBL] [Abstract][Full Text] [Related]
9. Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling.
Verheijen M; Schrooders Y; Gmuender H; Nudischer R; Clayton O; Hynes J; Niederer S; Cordes H; Kuepfer L; Kleinjans J; Caiment F
Toxicol Lett; 2018 Sep; 294():184-192. PubMed ID: 29803840
[TBL] [Abstract][Full Text] [Related]
10. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes.
Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H
Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells.
Holmgren G; Synnergren J; Bogestål Y; Améen C; Åkesson K; Holmgren S; Lindahl A; Sartipy P
Toxicology; 2015 Feb; 328():102-11. PubMed ID: 25529476
[TBL] [Abstract][Full Text] [Related]
13. A Targeted Metabolomics-Based Assay Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Identifies Structural and Functional Cardiotoxicity Potential.
Palmer JA; Smith AM; Gryshkova V; Donley ELR; Valentin JP; Burrier RE
Toxicol Sci; 2020 Apr; 174(2):218-240. PubMed ID: 32040181
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Changes in Morphology and Function of Human Induced Pluripotent Stem Cell Derived Cardiomyocytes (HiPSC-CMs) Cultured on an Aligned-Nanofiber Cardiac Patch.
Khan M; Xu Y; Hua S; Johnson J; Belevych A; Janssen PM; Gyorke S; Guan J; Angelos MG
PLoS One; 2015; 10(5):e0126338. PubMed ID: 25993466
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes.
Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J
Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214
[TBL] [Abstract][Full Text] [Related]
16. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes.
Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR
Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846
[TBL] [Abstract][Full Text] [Related]
17. Time-dependent evolution of functional vs. remodeling signaling in induced pluripotent stem cell-derived cardiomyocytes and induced maturation with biomechanical stimulation.
Jung G; Fajardo G; Ribeiro AJ; Kooiker KB; Coronado M; Zhao M; Hu DQ; Reddy S; Kodo K; Sriram K; Insel PA; Wu JC; Pruitt BL; Bernstein D
FASEB J; 2016 Apr; 30(4):1464-79. PubMed ID: 26675706
[TBL] [Abstract][Full Text] [Related]
18. Targeting HIF-1α in combination with PPARα activation and postnatal factors promotes the metabolic maturation of human induced pluripotent stem cell-derived cardiomyocytes.
Gentillon C; Li D; Duan M; Yu WM; Preininger MK; Jha R; Rampoldi A; Saraf A; Gibson GC; Qu CK; Brown LA; Xu C
J Mol Cell Cardiol; 2019 Jul; 132():120-135. PubMed ID: 31082397
[TBL] [Abstract][Full Text] [Related]
19. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
Yang X; Papoian T
J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
[TBL] [Abstract][Full Text] [Related]
20. Matrigel Mattress: A Method for the Generation of Single Contracting Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Feaster TK; Cadar AG; Wang L; Williams CH; Chun YW; Hempel JE; Bloodworth N; Merryman WD; Lim CC; Wu JC; Knollmann BC; Hong CC
Circ Res; 2015 Dec; 117(12):995-1000. PubMed ID: 26429802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
